Compare Rivian Automotive, Inc. (RIVN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Rivian Automotive, Inc. trades at $12.85 (market cap $18.75B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Rivian Automotive, Inc. is far larger — about 3.7× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RIVN | TVTX | |
|---|---|---|
Market Cap | $18.75B | $5.02B |
Volume | 23,581,407 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $67.52 |
52-Week Low | $12.50 | $26.79 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $18.79B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.
The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
